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Abstract 
 
Background: Sickle cell disease (SCD) is a multi-system disease characterised by vaso-
occlusive crisis, chronic anaemia and a shorter lifespan. More patients with SCD are living till 
reproductive age and contemplating pregnancy. Pulmonary complications in pregnancy are 
significant causes of maternal morbidity and mortality but yet this has not been systematically 
quantified. A systematic review and meta-analysis were conducted to quantify the association 
between SCD and pulmonary complications in pregnancy. 
 
Methods: MEDLINE, EMBASE, Web of Science, Cochrane and Maternity and Infant Care 
databases were searched for publications between January 1998 and April 2019. 
Observational studies involving at least 30 participants were included. Random effects 
models were used for statistical meta-analysis. The study was registered a priori with 
Prospero CRD42019124708. 
 
Findings: Twenty-two studies were included in the systematic review and eighteen in the 
quantitative analysis. The meta-analysis included 3964 pregnancies with SCD and 336559 
controls. Compared with women without SCD, pregnancies complicated by SCD were at 
increased risk of pulmonary thromboembolism (RR 7.74; 95% CI, 4.65-12.89). The estimated 
prevalence of ACS and pneumonia was 6.46% (95% CI, 4.66%-8.25%), with no significant 
difference between the HbSS and HbSC genotypes (RR, 1.42; 95% CI, 0.90-2.23).  
 
Interpretation: This meta-analysis highlighted a strong association between SCD and 
maternal pulmonary complications. Understanding the risks of and the factors associated with 
pulmonary complications would aid pre-conceptual counselling and optimal management of 
the condition in pregnancy, thereby reducing associated maternal morbidity and mortality.  
 
 
 
  
  
Key Messages 
 
What is the key question?  
To what extent are pregnant women with sickle cell disease at increased risks of pulmonary 
complications? 
 
What is the bottom line?  
Pregnancies with sickle cell disease are associated with an almost eight-fold increased risk of 
pulmonary thromboembolism and a prevalence of 6.5% for acute chest syndrome and 
pneumonia.  
 
Why read on? 
Understanding the risks of and the factors associated with pulmonary complications would 
aid pre-conceptual counselling and optimal management of the condition, thereby reducing 
associated morbidity and mortality. 
  
  
 
INTRODUCTION  
Sickle cell disease (SCD), as an autosomal recessive hemoglobinopathy, is a devastating multi-
organ disease characterised by vaso-occlusive crises and chronic anaemia [1]. It is one of the 
most common genetic disorders globally with over 300,000 children born with the condition 
each year [2]. The life expectancy is reduced for people with SCD [3]. With the introduction 
of neonatal screening for SCD and the increased awareness of the importance of antibiotic 
prophylaxis and multi-disciplinary management, more women are living till reproductive age 
and contemplating pregnancy [4]. In the UK, there are approximately 100-200 pregnancies in 
women with SCD per year [5]. Pregnancies complicated by SCD are associated with increased 
risk of adverse maternal and perinatal outcomes [6,7]  
 
Individual studies have shown that pregnant women with SCD are at increased risk of 
pulmonary complications. In particular, pulmonary complications including acute chest 
syndrome (ACS), pneumonia, pulmonary thromboembolism (PTE) and pulmonary 
hypertension (PH) are significant causes of maternal morbidity and mortality [8]. However, the 
heterogeneity inherent with the disease expression of SCD and with the setting of these studies 
leads to uncertainty when estimating the associated risks [9]. The lack of comprehensive data 
on pulmonary complications for pregnant women with SCD has led to difficulties in pre-
conceptual and antenatal counselling as well as clinical care pathways. The aim of this study 
is to systematically review and meta-analyse the risks of pulmonary complications in 
pregnancies complicated by SCD compared to pregnancies without SCD. In addition, we aim 
to evaluate whether the risk is greater for HbSS genotype compared to HbSC genotype, and to 
identify the proportion of maternal mortality associated with pulmonary complications.  
 
METHODS 
Search strategy  
A systematic review and meta-analysis were performed according to the Meta-analysis of 
Observation Studies in Epidemiology (MOOSE) group criteria and the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [10]. The following 
databases were searched for articles published between 20th Jan 1998 and 15th March 2019 
for titles and abstracts related to our research question: MEDLINE via Ovid, EMBASE, 
Cochrane, Web of Science, Maternity and Infant Care. Abstracts and full-text articles were 
reviewed by two assessors (S.I. and M.B.) independently and results were compared. In 
  
addition, we cross-examined references from relevant original papers and reviewed articles to 
identify further relevant studies. This systematic review and meta-analysis were limited to 
English language articles. The study was registered a priori with Prospero CRD42019124708. 
 
Study selection  
Studies were included in the systematic review if they met the following criteria: the study 
design was observational; the exposure of interest was SCD in pregnancy; pulmonary 
complications were reported and a minimum of thirty pregnant women with SCD were 
included as smaller studies tend to be of variable quality and add very little to the findings. We 
excluded animal studies, conference abstracts and manuscripts relating to sickle cell trait only.  
 
Data Extraction 
Data extraction was carried out independently by the two assessors using a standard extraction 
form. Two assessors undertook the screening for papers, read full-texts and assessed the final 
selection of papers. In the case of disagreement, a third assessor was consulted. The following 
information from each study was extracted: authors; year of publication; study name; study 
design; country of study, study setting, number of participants, relevant outcomes on 
pulmonary complications including ACS, PTE, pneumonia, PH and maternal mortality 
secondary to pulmonary complications. We obtained the gross national income per capita for 
each study location from World Bank data.  
 
Quality Assessment  
The Newcastle-Ottawa scale (NOS) was used to evaluate the quality of the papers [11]. The 
studies were evaluated with regards to three aspects: selection of the study groups, 
comparability of the groups and assessment of outcome, with a total of 9 stars available. The 
studies were categorised as high (7-9), medium (4-6) or low grade (1-3).(Table S2) 
 
Statistical analysis  
Analyses were pregnancy based. The main measure of effect of maternal SCD on pulmonary 
complications during pregnancy was the unadjusted risk ratio, calculated from the given 
numbers of pregnancies and events. We undertook separate comparisons for women with HbSS 
and HbSC genotypes, as well as for pregnancies managed in high-income and low- and middle-
income settings, for the prevalence of ACS and pneumonia. Depending on the outcome under 
consideration, studies with no events in either arm were excluded. To assess the association of 
  
each pulmonary complication in pregnancy for women with SCD, random effects models were 
used for statistical meta-analysis [12]. Heterogeneity of the studies was tested with the 
Breslow-Day test to measure inconsistency [13]. The level of heterogeneity was expressed as 
I2. An I2 score > 50% was agreed to indicate high heterogeneity. Publication bias (due to the 
non-publication of small, non-significant studies) was not relevant in discussing prevalence 
study as significance tests were not used. For PTE, there were too few studies (n=2) for a formal 
test. Based on the results obtained from the funnel plots, we used random effects model. We 
have used the continuity correction of a 0.5 when there were zero events. Stata version 15.1 
was used for all statistical analyses. 
 
RESULTS  
A flowchart for identification of papers and subsequent evaluations is shown in Figure 1. After 
the exclusion of ineligible papers, twenty-two papers were included for narrative review and 
eighteen papers for quantitative analysis. 
 
Figure 1. Flowchart of study selection  
 
Study Characteristics 
The characteristics of the studies included in the systematic review and meta-analysis are 
outlined in Table S1 [14-35]. 
Of the twenty-two studies included in the systematic review, four studies were prospective 
cohort studies, seventeen retrospective and one was both retrospective and prospective. 
Thirteen studies were from high-income countries (HIC) and nine were from low- or medium-
income countries (LMIC). Seven studies were considered to be of high quality and fifteen of 
medium quality (Table S2). The meta-analysis included 3964 pregnancies with SCD and 
336559 pregnancies without SCD. Of the twenty-two studies, eleven used pregnant women 
with normal hemoglobin (HbAA) as a control group and eleven studies did not include a control 
group.  
 
Prevalence of ACS and pneumonia in pregnant women with SCD 
 
Eighteen studies evaluated outcomes of ACS and pneumonia. Regarding the clinical case 
definition of ACS, four studies [20,26,30,32] applied the standard of new pulmonary 
signs/symptoms accompanied by new pulmonary infiltrates on chest X ray [36]; the other ten 
  
studies did not state a formal case definition. We have taken this into account when assessing 
the quality of the studies using the NOS scale [11]. In view of the difficulty in distinguishing 
ACS from pneumonia clinically, we have chosen to evaluate ACS/pneumonia as a combined 
outcome when assessing its prevalence.  
 
There was a strong evidence of heterogeneity (I2=89.29%). The funnel plot (figure 2) showed 
that the larger studies tended to have much smaller event rates.  Studies with event rates under 
5% were typically larger (mean size 383, compared to 90), but identified fewer cases (mean 
7.35, compared to 13.8). Because of this, some of the largest studies (Rajab et al [27] and Al 
Kahtani et al [17]) had bigger standard error and less accurate estimates (on the log scale) than 
smaller studies such as Silvia-Pinto et al [31], Soh et al [32] and Al-Farsi et al[14]. 
 
The meta-analysis and forest plot therefore considered event rates by sample size (Figure 3). 
The smaller studies (n <100 and n=100 to 150) gave estimates of 15.04% [95% confidence 
interval (CI), 8.18 to 21.91] and 10.07% (95% CI, 3.48 to 16.66).  For the six largest studies 
the estimate was 2.82% (95% CI, 1.33 to 4.31). The composite estimate was 6.46% (95% CI, 
4.66 to 8.25). Even after allowing for sample size, there was considerable heterogeneity which 
we were unable to explain. There was no significant difference in the prevalence of 
ACS/pneumonia between the HbSS and HbSC genotypes [relative risk (RR), 1.42; 95% CI, 
0.90 to 2.23] (Figure 4). LMIC (countries with a gross national income per capita of $30,000 
or less) had a higher prevalence of ACS/pneumonia (13.9%) compared to HIC (4.9%) (P=0.03) 
(Figure 5).   
 
Figure 2 – Funnel plot of studies investigating the prevalence of ACS/Pneumonia in pregnant 
women with SCD, by sample size 
 
Figure 3 - Forest plot of studies investigating the prevalence of ACS/Pneumonia in pregnant 
women with SCD, by sample size  
 
Figure 4- Forest plot of studies comparing the prevalence of ACS/Pneumonia in HbSS and 
HbSC genotype 
 
Figure 5- Forest plot of studies investigating the prevalence of ACS/Pneumonia in high-
income setting versus a low- middle- income setting. 
 
  
 
Pulmonary thromboembolism 
 
Of the six studies that reported outcome on PTE, only two included a control group of women 
with HbAA. The estimated prevalence of PTE in women with SCD in pregnancy was 
105/10,000 (95% CI, 65 to 170) and the estimated prevalence of PTE in women without SCD 
in pregnancy was 13.8/10,000 (95% CI, 12.5 to 15.1). There was nearly an eight-fold increased 
risk of PTE in women with SCD (RR 7.74; 95% CI, 4.65 to 12.89) (Figure 6).  
 
Figure 6 – Forest plot of studies investigating the association of SCD with PTE 
 
Pulmonary Hypertension 
There was only one study that looked at PH in pregnancy for women with SCD [33].  This 
study reported a statistically significant increase in the occurrence of PH in pregnancies with 
SCD compared to pregnancies without SCD, with an odds ratio of 6.3 (95% CI, 2.1-18.8) [33]. 
An additional study investigated women with a tricuspid regurgitant velocity (TRV)>2.5m/s, 
however, it was acknowledged that TRV>2.5m/s has a high false positive rate and does not 
reliably predict pulmonary hypertension [32]. 
 
Maternal deaths due to pulmonary complications 
 
Six studies reported maternal deaths and overall 88% of the maternal deaths reported were 
secondary to pulmonary complications [16,18,20,27,29,31]. Four studies provided no evidence 
of any autopsies being done. The studies from Ghana [18] and Jamaica [29] stated some 
autopsy-derived pulmonary pathologies (see Table 1). The true pathological causes of death in 
the other reported instances were unknown (see Table S3 for a series with systematic autopsy 
pathology). 
 
 
DISCUSSION  
This systematic review and meta-analysis identified a strong association between pregnancies 
with SCD and pulmonary complications, including ACS/pneumonia and PTE. In addition, 
pulmonary complications contributed substantially to maternal mortality in women with SCD. 
We believe this meta-analysis is the first review to provide pooled relative risks for pulmonary 
  
complications in women with SCD in pregnancy, and to present prevalence estimates of 
ACS/pneumonia according to genotype. This review was strengthened by a comprehensive 
search strategy and a large pooled sample size of almost 4000 pregnancies with SCD. It remains 
a limitation that a small number of women contributed more than one pregnancy to an 
individual study. Without individual patient data, it was not possible to take this into account. 
In addition, comparisons between groups of women (e.g. ACS/pneumonia prevalence in 
women with HbSS and HbSC) were not adjusted for possible confounding factors such as 
maternal age and parity as individual patient data was not available. 
 
The meta-analysis indicated that the prevalence of ACS/pneumonia is 6.46% for women with 
SCD during pregnancy. However, heterogeneity between studies was large, and the findings 
should be interpreted with caution. We acknowledge that ACS is a separate clinical entity to 
pneumonia with a different pathophysiology [36]. However, clinically the differentiation of 
ACS from other diagnoses, especially pneumonia, can often be challenging, and at times 
artificial. Therefore, we have reported ACS/pneumonia as a single outcome. Two studies 
observed that ACS occurred most frequently in the third trimester and early postpartum period 
[30,35], a finding that was also highlighted by a more recent study by Asare et al [37]. 
However, most included studies did not report on the timing of ACS therefore we were unable 
to stratify prevalence estimates by trimester. 
 
ACS/pneumonia prevalence was higher in LMIC compared to HIC. This finding was consistent 
with two recent systematic reviews and meta-analyses which indicated significantly higher 
maternal mortality for pregnancies with SCD in LMIC compared to HIC [6,7]. These findings 
are likely to reflect variations in treatment pathways and standards of care across settings. One 
study from a HIC was unique in reporting a management pathway involving prophylactic 
exchange transfusions. This may have altered their reported outcomes on pulmonary 
complications [24], although the evidence regarding any beneficial impact of prophylactic 
transfusion is inconsistent [38] [39]. There is evidence that maternal mortality due to 
pulmonary complications can be reduced with a multi-disciplinary approach. In a low-resource 
setting in sub-Saharan Africa, implementing a multidisciplinary care strategy with a joint 
obstetric haematology clinic reduced maternal mortality by 89% in a pre- and post-intervention 
study, and a comparable mortality rates to women without SCD can be achieved [40,41]. In 
settings in which multidisciplinary care for this population is already well established, further 
research is needed to identify areas of improvement. 
  
 
There was no statistically significant difference in the prevalence of ACS/pneumonia for 
women with HbSS genotype compared to HbSC genotype. This is in contrast to the general 
perception that HbSC is overall a clinically more benign phenotype than HbSS with regards to 
maternal and fetal complications [7]. The incidence of ACS in the general adult SCD 
population is known to be lower for adults with HbSC genotype (5.2 per 100 patient-years) 
when compared to HbSS genotype (12.8 per 100 patient-years) [42]. It may be that pregnancy 
is a specific process which heightens risk for women with HbSC. However, it should be noted 
that a small pooled sample size was used for the genotype-specific meta-analysis. In addition, 
some cases of HbSC might not be correctly depicted as HbSC. We note that two of the five 
studies included did not report on the method they used to distinguish the genotypes.  
 
The high prevalence of ACS/pneumonia in women with SCD may relate to the increased 
susceptibility to infections during pregnancy. Early recognition and prompt management of 
respiratory infections may reduce painful crises [15] and ACS [8,43]. The eight-fold increased 
risk of pulmonary thromboembolism in pregnancy in women with SCD confirms the need for 
appropriate thromboprophylaxis, especially for women with other risk factors (RCOG 
guideline 2015) [44]. 
 
Women with SCD, particularly those with PH, should get pre-conceptual counselling about the 
risks associated with pregnancy. Earlier studies identified a maternal mortality of 56% in 
pregnant women with secondary vascular PH [45] and women with PH are often advised 
against pregnancy [46]. A key public health issue to highlight is provision of appropriate 
contraceptive advice for women with SCD of reproductive age. Progestogens and intrauterine 
devices are effective and safe methods. There are some concerns with the use of combined oral 
contraceptive pill in this group of women but there is no evidence confirming it increases risk 
of thrombosis [2,47].  
 
Pulmonary complications contributed to the majority of maternal deaths, yet uncertainty 
remains regarding cause of death, particularly the pathogenesis of morbid complications in a 
disease where no diagnostic tissue pathology can be obtained in life. Complications including 
venous thromboembolism, amniotic fluid embolism, coagulopathy, PH, pneumonia, ACS and 
generalised sepsis can have overlapping clinical and imaging features (Table S3). Only a 
  
comprehensive autopsy can provide a true diagnosis [8]; this does not take place in many 
countries where SCD is most prevalent.  
 
Pregnant women with SCD are at high risk of pulmonary complications and associated 
mortality. This review and meta-analysis provides contemporary prevalence estimates of 
ACS/pneumonia and PTE in this population. This information can be used to aid pre-
conceptual counselling and to inform optimal management of SCD in pregnancy by 
highlighting the need for timely identification of pulmonary complications in this population. 
Delay in initiation of treatments and escalation of care have previously been identified by the 
Confidential Enquiry into Maternal Deaths as contributing to maternal deaths [48]. Further 
adequately powered research is needed to understand why HbSC genotype may be at similar 
risks of developing ACS/pneumonia during pregnancy to HBSS genotype. In addition, there is 
a paucity of data on the incidence of PH in pregnancies with SCD and in particular the 
management of PH. More work is needed to reduce the pre-pregnancy morbidities and 
occurrence of PH in women with SCD and there is an urgent need for studies to address how 
best to improve management of care of women with PH should they wish to continue with 
pregnancy. The prevalence of SCD is increasing globally. This review and meta-analysis 
should encourage renewed efforts to improve the clinical management, and thereby reduce the 
severe morbidity and mortality, of pregnant women with sickle cell disease.  
  
  
 
Table 1 - Maternal deaths due to pulmonary complications of sickle cell disease 
Study Maternal deaths due to pulmonary complications Total maternal deaths 
Al Julfairi (2016) [16] 2 due to PE, 1 due to ACS 4 
Asare (2018) [18]  8/44 deaths with autopsy report due to pulmonary embolism 
 33/44 deaths due to a clinical iagnosis of ACS* 
44 
Cardoso (2014) [20] 4 5 
Rajab (2006) [27] 3 4 
Serjeant (2004) [29] 1 autopsy-confirmed pneumonia and venous thromboembolism 2 
Silva-Pinto (2014) [31] 1 1 
Total deaths 53 60 
 
*Not all clinical diagnosis of ACS were subsequently confirmed on autopsy report.  
ACS = acute chest syndrome 
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